Skip to content

Comparison of catheters placed in the vein regarding the formation of blood clots

Peripheral insertion central catheter with Bioflo® technology versus Power Picc®: incidence and predictors of thrombosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-48342g
Enrollment
Unknown
Registered
2019-04-18
Start date
2017-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Extremity Deep Vein Thrombosis

Interventions

Intervention group (Insertion of PICC with endexo polymer in 517 hospitalized adult patients with a medical order of PICC). Control (Insertion of PICC without endexo polymer in 517 hospitalized adult
evaluation of the criteria related to the risks of deep venous thrombosis (DVT) according to the instruments of venous thromboembolism (VTE) and Clinical Algorithm. Step 5: Request signature of the in
Device

Sponsors

Hospital Israelita Albert Einstein
Lead Sponsor
Faculdade Israelita de Ciências da Saúde Albert Einstein
Collaborator

Eligibility

Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Hospitalized patients with intravenous therapy scheduled for 6 days or longer with a medical order for PICC insertion

Exclusion criteria

Exclusion criteria: Patients classified as urgency, because it prevented randomization; Patients who required a specific catheter for continuity of treatment; Patients who required a new PICC after being recruited for the study; Patients with a previous diagnosis of DVT; Patients previosuly mastectomized on the side chosen for insertion of the catheter; Patients with damaged/sclerosed peripheral venous network; Patients with bacteremia; Patients with dermatitis/cellulitis or trauma to the arm to be punctured.

Design outcomes

Primary

MeasureTime frame
A statistically significant decrease in the incidence of deep vein thrombosis diagnosed through doppler ultrasound in the presence of one of the signs and symptoms: pain, hyperaemia and edema.

Secondary

MeasureTime frame
Secondary outcomes will not be evaluated.

Countries

Brazil

Contacts

Public ContactEduarda dos Santos

Faculdade Israelita de Ciências da Saúde Albert Einstein

eduarda.santos@einstein.br+551121511001

Outcome results

None listed

Source: REBEC (via WHO ICTRP)